Health news round-up: GLP-1s for psoriasis, promise for people with cancer and pharmacogenomics A weekly summary of important developments in pharmacy and health news that you may have missed.…
NICE widens access to SGLT-2 inhibitors and GLP-1s in updated type 2 diabetes guidance The National Institute for Health and Care Excellence said the changes could prevent up to 17,000 deaths in the UK over three years.…
Over-the-counter medicines are being purchased by children as young as 13 years, reveals survey Overall, more than half of the survey respondents had used over-the-counter medicines in a six-month period.…
Two-fifths of children have seen weight-loss drugs online despite ban The results of a survey conducted by the Children’s Commissioner revealed that girls were more likely than boys to see adverts for weight-loss injections online.…
Health news round-up: medicines in pregnancy, GLP-1s and eating disorders, and new cancer treatments A weekly summary of important developments in pharmacy and health news that you may have missed.…
The dark side of the ‘miracle jab’: why eating disorder safety cannot be an afterthought As the use of glucagon-like peptide-1 receptor agonists increases, so must our awareness of patients who have an eating disorder or who are at risk of developing one.…
Health news round-up: travel warnings, AMR in children, and the latest on medicine supply A weekly summary of important developments in pharmacy and health news that you may have missed.…
Everything you need to know about GLP-1s for weight loss From semaglutide to tirzepatide, this article collates the latest information on pharmacological weight-loss treatments, including evidence and best practice for their use.…
Health news round-up: NICE approvals, surveillance data and GLP-1 warnings A weekly summary of important developments in pharmacy and health news that you may have missed.…
Managing neuropathic pain in bipolar disorder An overview of the clinical considerations for managing comorbid bipolar disorder and neuropathic pain.…
